Literature DB >> 26324804

Smoking and interstitial lung diseases.

George A Margaritopoulos1, Eirini Vasarmidi2, Joseph Jacob3, Athol U Wells1, Katerina M Antoniou4.   

Abstract

For many years has been well known that smoking could cause lung damage. Chronic obstructive pulmonary disease and lung cancer have been the two most common smoking-related lung diseases. In the recent years, attention has also focused on the role of smoking in the development of interstitial lung diseases (ILDs). Indeed, there are three diseases, namely respiratory bronchiolitis-associated ILD, desquamative interstitial pneumonia and pulmonary Langerhans cell histiocytosis, that are currently considered aetiologically linked to smoking and a few others which are more likely to develop in smokers. Here, we aim to focus on the most recent findings regarding the role of smoking in the pathogenesis and clinical behaviour of ILDs.
Copyright ©ERS 2015.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26324804     DOI: 10.1183/16000617.0050-2015

Source DB:  PubMed          Journal:  Eur Respir Rev        ISSN: 0905-9180


  16 in total

1.  Nicotine Modulates Growth Factors and MicroRNA to Promote Inflammatory and Fibrotic Processes.

Authors:  Afshin Ebrahimpour; Samana Shrestha; Mark D Bonnen; N Tony Eissa; Ganesh Raghu; Yohannes T Ghebre
Journal:  J Pharmacol Exp Ther       Date:  2018-11-16       Impact factor: 4.030

2.  The effect of cigarette smoking on the clinical and serological phenotypes of polymyositis and dermatomyositis.

Authors:  Adam Schiffenbauer; Sara Faghihi-Kashani; Terrence P O'Hanlon; Willy A Flegel; Sharon D Adams; Ira N Targoff; Chester V Oddis; Steven R Ytterberg; Rohit Aggarwal; Lisa Christopher-Stine; Ejaz A Shamim; Paul F Dellaripa; Sonye K Danoff; Andrew L Mammen; Frederick W Miller
Journal:  Semin Arthritis Rheum       Date:  2018-02-14       Impact factor: 5.532

3.  Rapidly non-ipf progressive fibrosing interstitial lung disease: a phenotype with an ipf-like behavior.

Authors:  Ngu Khine; Dalia Mudawi; Pilar Rivera-Ortega; Colm Leonard; Nazia Chaudhuri; George A Margaritopoulos
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2020-06-30       Impact factor: 0.670

4.  Pulmonary Langerhans cell histiocytosis: analysis of 14 patients and literature review.

Authors:  Cheng-Wei Li; Man-Hui Li; Jiang-Xiong Li; Ru-Jia Tao; Jin-Fu Xu; Wei-Jun Cao
Journal:  J Thorac Dis       Date:  2016-06       Impact factor: 2.895

5.  The effectiveness of immunosuppressive cyclosporin in attenuating the progression of interstitial lung diseases.

Authors:  Mathew Suji Eapen; Archana Vijay Gaikwad; Isobel E Thompson; Wenying Lu; Stephen Myers; Pawan Sharma; Sukhwinder Singh Sohal
Journal:  J Thorac Dis       Date:  2019-05       Impact factor: 2.895

Review 6.  Overlaps and uncertainties of smoking-related idiopathic interstitial pneumonias.

Authors:  So Hyeon Bak; Ho Yun Lee
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2017-11-01

7.  Quantitative evaluation of interstitial pneumonia using 3D-curved high-resolution CT imaging parallel to the chest wall: A pilot study.

Authors:  Hiroyasu Umakoshi; Shingo Iwano; Tsutomu Inoue; Yuanzhong Li; Shinji Naganawa
Journal:  PLoS One       Date:  2017-09-28       Impact factor: 3.240

8.  Primary tumor location is an important predictor of survival in pulmonary adenocarcinoma.

Authors:  Zhe Wang; Minghuan Li; Feifei Teng; Li Kong; Jinming Yu
Journal:  Cancer Manag Res       Date:  2019-03-21       Impact factor: 3.989

Review 9.  Action plans for COPD: strategies to manage exacerbations and improve outcomes.

Authors:  Leena Jalota; Vipul V Jain
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2016-06-02

10.  Expression of diaphragmatic myostatin and correlation with apoptosis in rats with chronic obstructive pulmonary disease.

Authors:  Xu Zhou; Daijiao Yi; Yanhong Wu; Xinghua Pei; Haiming Yu; Yanhong Chen; Yu Jiang; Wenpu Li
Journal:  Exp Ther Med       Date:  2018-01-02       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.